Dr. Reddy(RDY) ZACKS·2024-11-29 16:10Core Viewpoint - Dr. Reddy's Laboratories has launched a biosimilar of Coherus BioSciences' Loqtorzi (toripalimab) in India, branded as Zytorvi, targeting recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) [1][5] Company Developments - Dr. Reddy's has signed a licensing and commercialization agreement with Junshi Biosciences for Toripalimab, securing exclusive rights to develop and market the drug in 21 countries, including India [5][6] - The launch of Zytorvi makes India the third country globally to access this next-generation PD-1 inhibitor, following China and the United States [6] Product Information - Loqtorzi is an anti-PD-1 monoclonal antibody developed by Coherus in collaboration with Junshi Biosciences, recently approved by the FDA for RM-NPC treatment [2] - The drug has shown superior outcomes in clinical studies, demonstrating a 48% reduction in the risk of progression or death compared to standard chemotherapy [8] Market Context - The incidence of nasopharyngeal carcinoma is significant in India, with over 6,500 new cases reported in 2022, highlighting a substantial disease burden [7] - Dr. Reddy's shares have gained 1.2% year to date, while the industry has seen an 11.6% growth [4]